COMPANY

Nuvox Pharma, LLC

Keywords: glioblastoma

Location: Tucson, AZ · source · Oct 15, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.06M (SBIR Phase II 5R44CA298498-02, continuation, notice Aug 27, 2026). NIH RePORTER 5R44CA298498-02 (Aug 27, 2026)
Evidence (1 event)
- Aug 27, 2026 · NIH RePORTER 5R44CA298498-02
  Organization: NUVOX PHARMA, LLC; City/State: TUCSON, AZ; Project number: 5R44CA298498-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1057531; Administering IC: National Cancer Institute; Project title: Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 27, 2026 Grant Government grant — SBIR: $1.06M (annual award, as published), announced Aug 27, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 23, 2025 Grant Government grant — SBIR: $919,366 (annual award, as published), announced Sep 23, 2025. Agency: NIH/NCI. Source: government award database. source ↗
May 7, 2025 Grant Government grant — SBIR: $299,943 (annual award, as published), announced May 7, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Last 2 years.

Aug 27, 2026 Government grant — SBIR: $1.06M (annual award, as published), announced Aug 27, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 23, 2025 Government grant — SBIR: $919,366 (annual award, as published), announced Sep 23, 2025. Agency: NIH/NCI. Source: government award database. source ↗
May 7, 2025 Government grant — SBIR: $299,943 (annual award, as published), announced May 7, 2025. Agency: NIH/NINDS. Source: government award database. source ↗